^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
Published date:
10/05/2021
Excerpt:
This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy....The study cohort consisted of 128 patients who were diagnosed with non-small cell lung cancer (n = 50), melanoma (n = 31), small cell lung cancer (n = 14), urothelial carcinoma (n = 13), and other cancers (n = 20)....In the multivariate analyses, high sPD-L1 was an independent prognostic factor for both decreased PFS (HR 1.928, p = 0.038) and OS (HR 1.788, p = 0.004).
DOI:
10.1038/s41598-021-99311-y
